



Network Notification

Notice Date: October 1, 2026
To: Senior Care Options and One Care Providers
From: Commonwealth Care Alliance® (CCA)
Subject: November 2026 Updates to CCA's Medical Specialty Drug Policies
Effective Date: November 1, 2026

Summary

Effective November 1, 2026, Commonwealth Care Alliance® (CCA) is updating select Medical Specialty Drug Policies for our Senior Care Options (SCO) and One Care plans. To help you prepare, this communication outlines the policies that are changing and where to find additional information. We encourage you to review the "Summary of Changes" section within each policy to understand any updates that may affect the care of your CCA-covered patients. Medical Specialty Drug Policies can be accessed here: [Medical Necessity Guidelines | Commonwealth Care Alliance MA](#)

Bimonthly Policy Updates

Every other month you will receive a consolidated network notification summarizing all recent medical specialty drug policy changes. This helps you stay informed and up to date with minimal effort.

How to Use This Notification:

- Review the list of updated policies located here: [Medical Necessity Guidelines | Commonwealth Care Alliance MA](#)
- Note the effective date and the specific plans impacted by each policy.

Medical Specialty Drug Policy Updates

Policy	New or Revised
Alzheimer's Disease – Amyloid Beta-Directed Antibodies – Kisunla UM Medical	Revised
Alzheimer's Disease – Amyloid Beta-Directed Antibodies – Leqembi Intravenous UM Medical	Revised
Complement Inhibitors – Eculizumab Products UM Medical	Revised
Complement Inhibitors – Ultomiris UM Medical	Revised
Dermatology – Gene Therapy – Zevaskyn UM Medical	Revised
Diabetes – Tzield UM Medical	Revised
Enzyme Replacement Therapy – Elfabrio UM Medical	Revised
Erythropoiesis-Stimulating Agents – Aranesp UM Medical	Revised
Erythropoiesis-Stimulating Agents – Epoetin Alfa Products UM Medical	Revised

Policy	New or Revised
Fibrodysplasia Ossificans Progressiva – Pasatru UM Medical	New
Gamifant UM Medical	Revised
Graft-Versus-Host-Disease – Tregzi UM Medical	New
Hematology – Adzynma UM Medical	Revised
Hematology – Cablivi UM Medical	Revised
Hematology – Fibrinogen Products UM Medical	Revised
Hematology – Gene Therapy – Casgevy UM Medical	Revised
Hemophilia – Factor VIII Products UM Medical	Revised
Hereditary Angioedema – Dawnzera UM Medical	Revised
Human Immunodeficiency Virus – Yeztugo UM Medical	Revised
Hyaluronic Acid Derivatives (Intraarticular) UM Medical	Revised
Immune Disorders – Gene Therapy – Kresladi UM Medical	New
Immune Globulin – Intravenous UM Medical	Revised
Immune Globulin – Subcutaneous UM Medical	Revised
Immunologicals – Omalizumab Products UM Medical	Revised
Inflammatory Conditions – Infliximab Intravenous Products UM Medical	Revised
Multiple Sclerosis (Injectable – CD20-Directed Cytolytic Antibody) – Briumvi UM Medical	Revised
Multiple Sclerosis (Injectable – CD20-Directed Cytolytic Antibody) – Ocrevus Intravenous UM Medical	Revised
Multiple Sclerosis (Injectable – CD20-Directed Cytolytic Antibody) – Ocrevus Zunovo UM Medical	Revised
Multiple Sclerosis (Injectable – Other) – Lemtrada UM Medical	Revised
Multiple Sclerosis and Crohn's Disease (Injectable – Other) – Natalizumab Products UM Medical	Revised
Muscular Dystrophy – Gene Therapy – Elevidys UM Medical	Revised
Muscular Dystrophy – Viltepso UM Medical	Revised
Neurology – Imaavy UM Medical	Revised
Neurology – Rystiggo UM Medical	Revised
Neurology – Vyvgart Hytrulo UM Medical	Revised
Neurology – Vyvgart Intravenous UM Medical	Revised
Oncology (Injectable – Antibody-Drug Conjugate – CD19) – Monjuvi UM Medical	Revised
Oncology (Injectable – Antibody-Drug Conjugate – HER2) – Kadcyla UM Medical	Revised
Oncology (Injectable – Bispecific – BCMA-Directed) – Lynozyfic UM Medical	Revised
Oncology (Injectable – CAR-T) – Tecartus UM Medical	Revised
Oncology (Injectable – CD38-Directed Cytolytic Antibody) – Sarclisa Escena UM Medical	New
Oncology (Injectable – HER2 Antagonist) – Perjeta UM Medical	Revised
Oncology (Injectable – HER2 Antagonist) – Phesgo UM Medical	Revised
Oncology (Injectable – mTOR and PIK3CA Inhibitor) – Revtorpyk UM Medical	Revised

Policy	New or Revised
Oncology (Injectable – Programmed Death Receptor-1) – Keytruda Intravenous UM Medical	Revised
Oncology (Injectable – Programmed Death Receptor-1) – Keytruda Qlex UM Medical	Revised
Oncology (Injectable – Programmed Death Receptor-1) – Libtayo UM Medical	Revised
Oncology (Injectable – Programmed Death-Ligand 1) – Bavencio UM Medical	Revised
Oncology (Injectable – T-Cell Immunotherapy – MAGE-A4) – Tecelra UM Medical	Revised
Oncology (Injectable) – Bendamustine Products UM Medical	Revised
Oncology (Injectable) – Padcev UM Medical	Revised
Ophthalmology – Epioxa and Epioxa HD UM Medical	New
Ophthalmology – Lumvoa UM Medical	New
Ophthalmology – Vascular Endothelial Growth Factor Inhibitors – Aflibercept Products UM Medical	Revised
Ophthalmology – Vascular Endothelial Growth Factor Inhibitors – Lytenava UM Medical	New
Rituximab Intravenous Products UM Medical	Revised
Somatostatin Analogs – Lanreotide Products UM Medical	Revised
Somatostatin Analogs – Octreotide Long-Acting Products UM Medical	Revised
Spinal Muscular Atrophy – Gene Therapy – Itvisma UM Medical	Revised
Spinal Muscular Atrophy – Gene Therapy – Zolgensma UM Medical	Revised
Spinal Muscular Atrophy – Spinraza UM Medical	Revised
Transplantation – Nulojix UM Medical	Revised
Uplizna UM Medical	Revised
Xiaflex UM Medical	Revised

Questions?

For more information, please contact CCA Provider Services at 1-866-420-9332. Hours of availability are 8:00 a.m. to 5:00 p.m. Monday through Wednesday and Friday, and on Thursdays from 8:30 a.m. to 5:00 p.m., Eastern Time (ET).

Thank you for your continued partnership and for the care you provide for our members.

MA-Multi-P-6186344